Skye Bioscience, Inc.
SKYE
$1.11
-$0.10-8.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.91M | 3.91M | 4.56M | 2.87M | 85.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | 0.00 | -- |
| Total Operating Expenses | 13.26M | 18.24M | 11.76M | 10.67M | 4.97M |
| Operating Income | -13.26M | -18.24M | -11.76M | -10.67M | -4.97M |
| Income Before Tax | -12.75M | -17.62M | -11.10M | -9.75M | -3.90M |
| Income Tax Expenses | -- | 3.40K | 2.00K | 0.00 | -- |
| Earnings from Continuing Operations | -12.75M | -17.62M | -11.10M | -9.75M | -3.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.75M | -17.62M | -11.10M | -9.75M | -3.90M |
| EBIT | -13.26M | -18.24M | -11.76M | -10.67M | -4.97M |
| EBITDA | -13.09M | -18.06M | -11.58M | -10.49M | -4.90M |
| EPS Basic | -0.32 | -0.44 | -0.28 | -0.24 | -0.10 |
| Normalized Basic EPS | -0.20 | -0.28 | -0.18 | -0.15 | -0.06 |
| EPS Diluted | -0.32 | -0.44 | -0.28 | -0.24 | -0.10 |
| Normalized Diluted EPS | -0.20 | -0.28 | -0.18 | -0.15 | -0.06 |
| Average Basic Shares Outstanding | 39.67M | 39.66M | 39.65M | 39.97M | 38.82M |
| Average Diluted Shares Outstanding | 39.67M | 39.66M | 39.65M | 39.97M | 38.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |